Renal Cancer Drug Companies

Merck (MSD) FDA Priority Review granted for their sNDA for Welireg (a HIF-2α inhibitor) for previously treated RCC patients, with potential approval by January 17, 2024.Positive Phase III LITESPARK-005 trial results demonstrating Welireg's efficacy in extending progression-free survival (PFS) in advanced RCC patients.

Pfizer Expanded use of Bavencio (avelumab) with atezolizumab (Tecentriq) as first-line treatment for advanced RCC, as recommended by the National Comprehensive Cancer Network (NCCN) guidelines.

Invectys FDA Fast Track designation granted for their CAR-T therapy IVS-3001 for the treatment of RCC.

Bristol Myers Squibb Phase II clinical trial initiated for Nivolumab (Opdivo) in combination with Cabozantinib for treatment of papillary RCC.

List of Renal Cancer Drug Key Companies in the Market

• Novartis AG (Switzerland)


• Pfizer Inc. (US)


• GlaxoSmithKline plc (UK)


• Genentech Inc. (US)


• Hoffmann-La Roche AG (Switzerland)


• Cipla Limited (India)


• Active Biotech AB (Sweden)


• Amgen (US)


• Bayer AG (Germany)


• Bristol-Myers Squibb company (US)